Selected article for: "antiviral attractive candidate and attractive candidate"
Author: Allegretti, Marcello; Cesta, Maria Candida; Zippoli, Mara; Beccari, Andrea; Talarico, Carmine; Mantelli, Flavio; Bucci, Enrico M.; Scorzolini, Laura; Nicastri, Emanuele
Title: Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection
  • Cord-id: ant9wbq2
  • Document date: 2021_8_17
    • ID: ant9wbq2
    Snippet: The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates strategies to identify prophylactic and therapeutic drug candidates to enter rapid clinical development. This is particularly true, given the uncertainty about the endurance of the immune memory induced by both previous infections or vaccines, and given the fact that the eradication of SARS-CoV-2 might be challenging to reach, given the attack rat
    Document: The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates strategies to identify prophylactic and therapeutic drug candidates to enter rapid clinical development. This is particularly true, given the uncertainty about the endurance of the immune memory induced by both previous infections or vaccines, and given the fact that the eradication of SARS-CoV-2 might be challenging to reach, given the attack rate of the virus, which would require unusually high protection by a vaccine. Here, we show how raloxifene, a selective estrogen receptor modulator with anti-inflammatory and antiviral properties, emerges as an attractive candidate entering clinical trials to test its efficacy in early-stage treatment COVID-19 patients.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abdominal pain and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abdominal pain and additional risk: 1, 2, 3, 4
    • action antiviral mechanism and acute lung injury: 1
    • action antiviral mechanism and acute respiratory syndrome: 1, 2, 3, 4, 5
    • action antiviral mechanism and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5
    • action antiviral mechanism and adaptive innate: 1
    • activation function and acute ards respiratory distress syndrome: 1, 2, 3, 4
    • activation function and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • activation function and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • activation function and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • activation function domain and acute respiratory syndrome: 1
    • activation function domain and acute respiratory syndrome coronavirus: 1
    • active ingredient and acute ards respiratory distress syndrome: 1
    • active ingredient and acute ards respiratory distress syndrome progress: 1
    • active ingredient and acute lung injury: 1, 2
    • active ingredient and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • active ingredient and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • active treatment group and acute respiratory syndrome coronavirus: 1